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METHODOLOGY
One-step immortalization of primary 
human airway epithelial cells capable 
of oncogenic transformation
Jordan L. Smith1,2†, Liam C. Lee1,3†, Abigail Read1, Qiuning Li1,4, Bing Yu1,5, Chih‑Shia Lee1 and Ji Luo1* 
Abstract 
Background: The ability to transform normal human cells into cancer cells with the introduction of defined genetic 
alterations is a valuable method for understanding the mechanisms of oncogenesis. Easy establishment of immortal‑
ized but non‑transformed human cells from various tissues would facilitate these genetic analyses.
Results: We report here a simple, one‑step immortalization method that involves retroviral vector mediated co‑
expression of the human telomerase protein and a shRNA targeting the CDKN2A gene locus. We demonstrate that 
this method could successfully immortalize human small airway epithelial cells while maintaining their chromosomal 
stability. We further showed that these cells retain p53 activity and can be transformed by the KRAS oncogene. 
Conclusions: Our method simplifies the immortalization process and is broadly applicable for establishing immortal‑
ized epithelial cell lines from primary human tissues for cancer research.
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The evolution of cancer cells involves the acquisition of 
mutations that often fall within a set of defined genetic 
pathways. Experimental transformation of normal human 
cells into cancer cells through the introduction of defined 
oncogenic lesions represents a major breakthrough in 
cancer research, as this approach enables the step-by-
step re-construction of the oncogenic process. It has 
been established that multiple alterations are required to 
transition primary human epithelial cells to a neoplastic/
cancerous state in  vitro. Primary human cells cultured 
in  vitro experience two proliferation blockades, senes-
cence and crisis [1]. When grown in chemically defined 
media without feeder cells, primary human epithelial 
cells undergo rapid senescence that is likely a result of 
cell culture stress [2]. Cell culture senescence is associ-
ated with the up-regulation of the tumor suppressor 
p16INK4A and the subsequent activation of the Rb protein. 
Senescence can be bypassed with expression of viral 
oncoproteins that neutralize Rb and p53 activity [3–5]. 
These include the SV40 polyomavirus Large T (LgT) anti-
gen [6, 7], the adenovirus E1A protein [1, 3, 5, 8], and the 
papillomavirus E6 and E7 proteins [2, 6, 9–11]. Human 
cells that have by-passed senescence still have limited 
replicative potential due to insufficient telomerase activ-
ity, and they eventually encounter crisis due to progres-
sively shortening telomeres [1, 12, 13]. Re-expression of 
the catalytic subunit of telomerase, hTERT, which is suf-
ficient to restore telomerase activity in many cell types 
[2, 14], can prevent telomere erosion, maintain genomic 
stability and immortalize cells [3–5, 15–18]. Historically, 
primary human cells have been immortalized through a 
two-step process: the first step involves the introduction 
of the aforementioned viral oncoproteins to neutralize Rb 
and p53 activity to bypass cell culture senescence [4, 6, 
7]. The second step involves the introduction of hTERT, 
which serves to maintain telomere stability and prevent 
crisis [13]. Primary human epithelial cells immortalized 
this way can be successfully transformed by oncogenes 
such as Ras [19, 20]. This step-wise approach provides 
a valuable means to model malignant transformation 
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under genetically defined conditions. Since most human 
cancer cells do not harbor viral oncoprotein expression, 
recent studies have sought to obviate the need for viral 
oncoproteins. It has been shown that the over-expression 
of the G1 cell cycle kinase CDK4 [21, 22] or shRNA-
mediated knockdown of p16INK4A [23, 24] can immortal-
ize cells in the presence of hTERT.
Lung cancer is a leading cause of cancer-related mor-
tality in the United States and worldwide. Approxi-
mately  ~80% of lung cancer are non-small cell lung 
cancer (NSCLC) that is thought to originate from epi-
thelial cells of the small airway or the alveolus [25–27]. 
Sequencing studies and copy number variation analyses 
have revealed that human lung adenocarcinomas fre-
quently harbor mutations in KRAS, TP53 and CDKN2A 
[28, 29]. Previously, several studies have showed that 
NSCLC can be modeled in vitro with human airway and 
bronchial epithelial cells [20, 30, 31]. In these studies, pri-
mary airway and bronchial epithelial cells were immortal-
ized using hTERT together with either viral oncoproteins 
[30] or CDK4 overexpression [21]. Subsequent introduc-
tion of oncogenes such as KRAS could transform these 
cells and enable tumor growth in vivo [20, 30, 31].
Here we developed a simplified, one-step immortali-
zation method for primary human cells and we demon-
strated its utility in immortalizing human small airway 
epithelial cells (SAECs). We showed that immortalized 
SAECs are chromosomally stable and can be transformed 
by the KRAS oncogene in  vitro. This approach should 
facilitate the establishment of isogenic panels of normal 
and transformed human cell lines for the study of malig-
nant transformation.
Results
One‑step immortalization of small airway epithelial cells
In the absence of feeder cells, the standard immortaliza-
tion protocols for human epithelial cells typically involve 
a two-step process. First viral oncoproteins are intro-
duced to bypass p16INK4A and p53 dependent prolif-
eration blockade induced by cell culture stress. Second, 
hTERT is re-expressed to prevent crisis and maintain 
genomic stability. To simplify the immortalization pro-
tocol and to avoid the use of viral oncoproteins, we 
designed a retroviral vector, MSCV-pic2, that is capa-
ble of co-expressing a shRNA and a cDNA on the same 
selectable marker (Fig. 1a). Using this vector, we simulta-
neously introduced into primary human SAECs a hTERT 
cDNA and a shRNA against the human CDKN2A locus 
that targets both the p16INK4A and p14ARF proteins (here-
after referred to as sh_p16). We reasoned that this should 
allow cells to proliferate both continuously while main-
taining genomic stability in chemically defined media 
without feeder cells.
To validate our one-step immortalization approach, we 
engineered additional constructs that expressed a nega-
tive control shRNA targeting firefly luciferase (sh_ctrl) 
instead of sh_p16, and constructs that expressed the 
enhanced green fluorescent protein (EGFP) instead of 
hTERT. We transduced primary SAECs with these con-
structs and generated stable, polyclonal cell lines follow-
ing drug selection. In the untransduced cells, p16INK4A 
protein was expressed at moderate levels, whereas p14ARF 
protein was expressed at very low levels (Fig. 1b, lane 1). 
Since our sh_p16 targets a common exon shared by both 
p16INK4A and p14ARF, it knocked down both proteins by 
western blot (Fig. 1b, lanes 4, 5). To verify the activity of 
the hTERT cDNA, we used a PCR-based telomeric repeat 
amplification protocol (TRAP) assay to confirm that tel-
omerase activity was indeed elevated in cells expressing 
hTERT but not in cell expressing EGFP (Fig. 1c).
Next, we evaluated the proliferation capacity of SAECs 
stably expressing various combinations of hTERT and 
Fig. 1 Characterization of retroviral vector for one‑step immortaliza‑
tion. a Schematics of the MSCV‑pic2 vector design. For one‑step 
immortalization, a hTERT cDNA and a shRNA targeting p16INK4A and 
p14ARF were introduced into this vector. b Western blot verifying the 
knockdown of p16INK4A and p14ARF in stably transduced SAECs. c Tel‑
omerase activities in SAECs stably transduced with hTERT cDNA (error 
bars represent SD for all bar charts unless otherwise stated)
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sh_p16. Similar to previous studies on airway epithe-
lial cells [21], untransduced primary SAECs, as well as 
SAECs transduced with EGFP plus sh_ctrl only prolifer-
ated for a short period before senescing. SAECs express-
ing EGFP plus sh_p16, on the other hand, were able to 
bypass cell culture senescence and continue to prolifer-
ate for ~45 population doublings (PDs) before arresting, 
presumably as a result of reaching the Hayflick limit [12]. 
SAECs expressing hTERT plus sh_p16 were able to prolif-
erate pass the Hayflick limit and maintain log phase pro-
liferation beyond 70 PDs (Fig. 2a). Together, these results 
indicate that primary human epithelial cells can be suc-
cessfully immortalized in a one-step process using our 
single vector system that that co-expresses hTERT and 
sh_p16. We thus referred to these immortalized SAECs 
as iSAECs.
iSAEC morphology and genomic stability
Morphologically, iSAECs at early passage 19 (P19) 
and late passage (P71) exhibit similar features under 
phase-contrast microscopy (Fig.  2b). In contrast to BJ 
fibroblasts, iSAECs expressed the epithelial marker kera-
tin-19, similar to the NSCLC cell line HCC4006 (Fig. 2c). 
Western blots showed that iSAECs expressed the epithe-
lial marker E-cadherin, although they also expressed the 
mesenchymal marker vimentin at a low level (Fig.  2d). 
Thus we concluded that iSAECs have largely retained 
their epithelial characteristics throughout the immortali-
zation process.
Next, we wanted to confirm that our genetic manipula-
tion did not affect genomic stability in iSAECs. Cell cycle 
profiles of early passage (P19) and late passage (P71) 
SAECs showed that late passage cells have reduced G1 
Fig. 2 Characterization of the proliferation and morphology of iSAECs. a Population doubling (PD) curves for SAECs transduced with indicated 
cDNA and shRNA pairs. Only SAECs transduced with hTERT cDNA and sh_p16 were able to proliferate indefinitely. b Morphology of early and late 
passages (P19 and P71, respectively) iSAEC cells. c Expression of the epithelial marker keratin 19 (KRT19) in iSAECs. BJ fibroblasts and the NSCLC 
cell line HCC4006 were used as negative and positive controls, respectively. KRT19 mRNA levels were normalized to beta‑actin. d Expression of 
E‑cadherin and vimentin in iSAECs. BJ fibroblasts and the NSCLC cell line HCC4006 were used as controls
Page 4 of 8Smith et al. Cell Biosci  (2016) 6:57 
population and increased S phase population, although 
G2/M population remained similar (Fig.  3a). We evalu-
ated the ploidy of iSAECs at early and late passages 
against early passage (P18) BJ fibroblasts using meta-
phase spreads. The majority of the iSAECs retained 
euploidy at both early and late passages (Fig.  3b), indi-
cating that they were chromosomally stable. We noted 
that the early iSAECs tended to have higher fraction of 
hypo-diploid cells with 45 chromosomes, which might 
be a result of chromosome loss during sample prepara-
tion. Lastly, we stained late passage iSAECs for telomeres 
using PNA-Cy3 telomere probes. All chromosome ends 
stained positive for telomere and no chromosome fusions 
were observed (Fig.  3c). Together, these results indicate 
that iSAECs are chromosomally stable.
Oncogenic transformation of iSAECs by mutant KRAS
We designed our immortalization system with the goal 
of keeping some degree of intact p53 response. Because 
the sh_p16 shRNA targets both the p16INK4 and p14ARF 
proteins, we recognize that the p14ARF-mediated regu-
lation of p53 function is likely to be affected. However, 
because in SAECs p14ARF level was very low to begin with 
(Fig. 1b), we reason that p53 response should at least be 
partially preserved in iSAECs. Indeed, p53 protein was 
readily detectable in iSAECs when compared to the osteo-
sarcoma cell line U2OS which retains WT p53 expression 
(Fig.  4a). Furthermore, when iSAECs were treated with 
the DNA damage agent doxorubicin, both p53 phospho-
rylation and the induction of the p53 target protein p21 
were robustly induced in iSAECs (Fig.  4a). Of note and 
different from U2Os cells, doxorubicin treatment did not 
substantially increase total p53 protein level in iSAECs. In 
addition, when we introduced a p53 shRNA (sh_p53) into 
iSAECs, we were able to deplete p53 and ablate doxoru-
bicin-induced p21 induction (Fig. 4a). Thus, we concluded 
that iSAECs retain p53 function and this allows the inde-
pendent manipulation of p53 activities in these cells.
Lastly, we wished to determine how iSAECs would 
respond to oncogenic transformation by the KRAS onco-
gene. We generated iSAECs stably expressing HA-tagged 
WT KRAS protein (KRASWT) or the constitutively active 
mutant KRAS-G12V protein (KRASV12) under the con-
trol of a tetracycline (tet)-inducible promoter. In these 
cells, doxycycline treatment leads to a dose-dependent 
induction of HA-KRAS (Fig.  4b). Unexpectedly, induc-
tion of KRASV12 did not dramatically activate the MAPK 
pathway as measured by ERK kinase phosphorylation 
(Fig.  4b). Neither was this level of KRASV12 expression 
able to confer anchorage-independent grow in soft aga-
rose. We next used a tet-inducible EGFP-KRASV12 fusion 
construct which can be expressed at a higher level to ele-
vate phospho-ERK level (Fig. 4c). Under these conditions 
the mutant EGFP-KRASV12 protein enabled AI colony 
formation (Fig.  4d). However, the clonogenic efficiency 
was low and only ~0.5% of cells formed soft agarose colo-
nies. Thus, iSAECs are capable of being transformed by 
the KRAS oncogene at a low efficiency, and it is likely that 
additional genetic perturbations are required for their 
full transformation [31].
Fig. 3 iSAECs are genomically stable. a Cell cycle distribution of 
early and late passage iSAECs in log phase culture (p values were 
determined using Student’s t test for all bar charts). b Chromosomal 
count of early and late passages (P14 and P79, respectively) iSAECs 
using metaphase spread of colcemid arrested mitotic cells. Early 
passage (P18) BJ fibroblasts were used as control. Numbers in each 
column indicates the number of metaphase spreads analyzed. c 
Telomere fluorescence in situ hybridization of late passage iSAECs. A 
representative metaphase spread image was shown
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Discussion
In this study, we developed a method that enables the 
one-step immortalization of human primary epithelial 
cells through the simultaneous introduction of hTERT 
cDNA and a shRNA against the CDKN2A locus. We 
demonstrate that this approach led to the establish-
ment of immortalized cells capable of replication beyond 
the Hayflick limit [12] while maintaining telomeres and 
genomic stability.
We avoided using viral oncoproteins such as LgT, E6 
and E7 in our approach as these proteins inactivate both 
the Rb and p53 pathway. We demonstrate that p16INK4A 
knockdown in combination with hTERT was sufficient 
for cell immortalization, similar to a previous report 
[24]. Due to the shared exon usage between p16INK4A 
and p14ARF proteins, we were unable to identify a potent 
shRNA that selectively knockdown p16INK4A but not 
p14ARF. However, in the case of SAECs, p14ARF expres-
sion level was very low and its depletion did not lead to 
loss of p53 proteins. Indeed, we found that in proliferating 
iSAECs p53 was expressed and could be readily activated 
by DNA damage. Thus, p53 function is at least partially 
preserved in iSAECs and full p53 inactivation may not 
be an obligatory requirement for the immortalization of 
these cells [21, 24]. Interestingly, in iSAECs, total p53 pro-
tein level was not substantially elevated by DNA damage. 
This was unexpected as phosphorylation typically stabi-
lizes p53 by interfering with its binding to the E3 ligase 
MDM2 [32]. Whether this phenomenon is specific to 
SAECs or is associated with our particular method of cell 
immortalization require further investigation. Neverthe-
less, our approach allows p53 activity to be manipulated 
separately, as we demonstrated with shRNA mediated p53 
knockdown. This is a useful feature as it enables the study 
of genetic interaction between p53 and other oncogene 
and tumor suppressors in this model system.
In iSAECs, the introduction of the KRAS oncogene 
could drive soft-agarose colony growth. However, the 
Fig. 4 Response of iSAECs to p53 activation and KRAS oncogene 
transformation. a Induction of p53 by DNA damage in iSAECs. iSAECs 
with or without stable expression of a p53 shRNA (sh_p53) were 
treated for 24 h with 200 nM doxorubicin and phospho‑p53 (Ser15) 
and p21 levels were measured by western blot. The p53 WT U2OS 
cells were included as a positive control. b Expression of tetracyclin 
(tet)‑inducible HA‑tagged KRASWT and KRASV12 proteins in iSAECs. 
iSAECs stably expressing KRAS cDNA were treated with 100 ng/ml 
doxycycline for various periods of time and the level of KRAS and 
phospho‑ERK (Thr202/T204) protein were measured. c Expression of 
tetracyclin (tet)‑inducible EGFP‑tagged KRASWT and KRASV12 proteins 
in iSAECs. iSAECs stably expressing inducible KRAS cDNA were 
treated with 100 ng/ml doxycycline for 2 days and the level of KRAS 
and phospho‑ERK protein were measured. d Soft agarose anchorage‑
independent (AI) colony assay of iSAECs cells following induction of 
EGFP‑KRASWT and EGFP‑KRASV12 proteins. 5000 iSAECs were seeded 
in soft‑agarose media with or without 100 ng/ml doxycycline and the 
colony numbers were counted 16 days later. The percentage values 
above each bar graph indicate clonogenic efficiency as a % of the 
total number of cells seeded
▸
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transformation efficiency was low and it required rela-
tively high levels of KRAS expression. Our findings thus 
indicate that human airway epithelial cells are relatively 
resistant to malignant transformation elicited by a sin-
gle oncogene. This is in agreement with previous studies 
indicating that KRAS alone was unable to fully transform 
immortalized airway epithelial cells and cooperation 
from additional oncogenes including PIK3CA and MYC 
are necessary for their full transformation [20, 22, 31].
A convenient method to immortalize cells serves two 
valuable purposes. First, immortalized cells such as 
iSAECs provide a starting point for the evaluation of 
oncogene and tumor suppressor function in a prospective, 
isogenic setting. This enables step-wise reconstruction 
of the oncogenic process by the introduction of defined 
genetic changes [19, 20, 22, 30, 31]. Second, immortalized 
but non-transformed epithelial cells are valuable “normal” 
controls for tumor cell lines for evaluating drug target and 
drug candidate toxicity. Currently, many human cancer 
cell lines lack “normal” counterparts from the same tissue. 
Although we only tested SAECs in this study, it is likely 
that, with the appropriate media conditions, our approach 
should facilitate the creation of immortalized epithelial 
cell lines from various tissues for cancer research.
Methods
Cell culture and pharmacological agents
Primary human small airway epithelial cells were pur-
chased from Lonza. Cells were cultured in SAGM growth 
media (Lonza). BJ Fibroblasts (ATCC) were cultured 
in eagle’s minimum essential medium (ATCC) supple-
mented with 10% heat inactivated fetal bovine serum 
(Hi-FBS, Life Technologies) and 100 units/mL penicillin 
plus 100  µg/ml streptomycin (P/S, Lonza). U2OS cells 
were cultured in McCoy’s 5A Media (Lonza) supple-
mented with 10% Hi-FBS and P/S. Cells were maintained 
at 37 °C in 5% CO2. Doxorubicin was used at a concentra-
tion of 200  nM for cell culture treatment. KaryoMAX® 
Colcemid™ Solution in PBS (Life Technologies) was used 
at a concentration of 0.1 ug/mL for metaphase spreads. 
Doxycycline was from Sigma.
Plasmid construction and generation of stable cell lines
MSCV-pic2 is a retroviral vector that co-expresses a 
cDNA and a shRNA. For one-step immortalization, we 
introduced into this vector the cDNA of the catalytic 
subunit of hTERT and a shRNA for the CDKN2A gene 
locus that knocks down both p16INK4A and p14ARF. Plas-
mids generated using the MSCV-pic2 vectors include: 
MSCV-pic2-neo-hTERT-sh_p16, MSCV-pic2-neo-
EGFP-sh_p16, MSCV-pic2-neo-hTERT-sh_Ctrl, MSCV-
pic2-neo-EGFP-sh_Ctrl. The shRNA target sequences 
were: sh_p16 (ACTCGGGAAACTTAGATCATCA), 
sh_p53 (CCCGGCGCACAGAGGAAGAGAA), sh_Ctrl 
(firefly luciferase shRNA CCCGCCTGAAGTCTCT-
GATTAA). The lentiviral tet-inducible vectors express-
ing EGFP-KRAS V12 and WT proteins were described 
before [33]. Plasmids were packaged in 293T cells with 
Trans-IT-293 Transfection Reagent (Mirus Bio). SAECs 
were transduced by spin infection at 1800 RPM for 
45  min. Stable cell lines were generated using the drug 
selectable markers associated with each vector.
Western blots
Cells were lysed directly with Laemmli sample buffer. 
Whole cell lysates were boiled for 10  min at 95  °C and 
subsequently stored at −80  °C. Whole cell lysates were 
separated using BioRad Mini-Protean TGX 4–20% 
resolving gels. The protein was then transferred to a 
nitrocellulose membrane. The source of antibodies were: 
p16INK4A (BD Bioscience #551153), p14ARF (Bethyl, A300-
340A), p53 (Santa Cruz #DO-1 SC-126), p21 (Calbio-
chem #OP64) Vinculin (Sigma #V9131), GAPDH (Santa 
Cruz #SC-25778) and phospho-p53-S15 (Cell Signaling 
Technology #9284), KRAS (Sigma, clone 4F3), phospho-
ERK (Cell Signaling Technology, #4377), total ERK (Cell 
Signaling Technology, #9102), phospho-Akt (Cell Signal-
ing Technology, #4058), Akt (Cell Signaling Technology, 
#9272), E-Cadherin (Cell Signaling Technology, #24E10), 
N-Cadherin (Cell Signaling Technology, #13116), Vimen-
tin (Cell Signaling Technology, #5741). Blots were devel-
oped using conjugated anti-rabbit or anti-mouse and 
either Luminata Forte (Millipore) substrate or SuperSig-
nal West Femto (Pierce) substrate on an Alpha Innotech 
HD2 Western Blot Imaging Station (protein Simple). 
Images were quantified with Alpha Innotech Image Soft-
ware or Adobe Photoshop. Cropping and contrast adjust-
ment were applied to entire images consistently without 
local alterations.
Quantitative reverse transcription PCR
RNA was extracted from early and late passage iSAECs, 
BJ Fibroblasts, and HCC4006 NSCLC cell line using the 
RNA easy Kit and QiaShredder Columns (Qiagen). Col-
lected RNA was reverse transcribed to cDNA using Mul-
tiscribe Reverse Transcriptase (Applied Biosystems). 
Real-time PCR was performed on the ABI 79300HT Real-
Time Thermo Cycler with SYBR Green using the follow-
ing primers pairs: KRT19_F (ACCAAGTTTGAGACG 
GAACAG) and KRT19_R (CCCTCAGCGTACTGAT 
TTCC), B-Actin_F (AGAGCTACGAGCTGCCTGAC) 
and B-Actin_R (AGCACTGTGTTGGCGTACAG). All 
mRNA levels were normalized to B-Actin levels and 
KRT19 levels in BJ Foreskin Fibroblasts. mRNA levels are 
the average of three technical replicates, and error bars 
are standard deviation.
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Cell cycle analysis flow sorting
Log phase iSAEC passage 19 (P19) and iSAEC (P71) 
were collected, stained and fixed with propidium iodide 
(Sigma-Aldrich). Cells were scanned with a FACS Calibur 
analyzer (Beckson-Dickinson) and the data acquired with 
CellQuest Pro software. FACS profiles were analyzed 
using ModFit LT for all samples. The experiment was 
performed with three biological replicates of iSAECs.
Metaphase spreads, FISH, and microscopy
Log-phase, iSAEC (P14), iSAEC (P79) and BJ Fibroblasts 
(P18) were treated with KaryoMAX® Colcemid™ Solu-
tion in PBS at 0.1 ug/mL for 6 h at 37  °C. Mitotic frac-
tions of cells were collected and pre-warmed 75  mM 
hypotonic solution was added to the mixture and incu-
bated at 37  °C for 25  min. Mitotic cells were fixed in a 
solution of 3:1 v/v Methanol to Acetic Acid. Slides were 
prepared and stained with SlowFade® Gold Antifade 
Mountant with DAPI (Life Technologies). Metaphase 
spreads were imaged with Zeiss Axio Microscope on a 
63× Oil Objective. Metaphase spreads were quantified 
manually using Adobe Photoshop for labeling and isola-
tion of chromosomes. Metaphase spreads of iSAEC (P61) 
were prepared as described above. Before the addition 
of DAPI, slides were stained with Telomere PNA Cy3 
probe (DAKO) according to the manufacturer’s instruc-
tions and then cross-stained with SlowFade® Gold Anti-
fade Mountant with DAPI. Telomere probe slides were 
imaged with Zeiss Axio Imager on a 63× Oil Objective.
Telomerase assay
Telomerase activity was quantified using the TRAPEZE 
RT Telomerase Detection Kit (Millipore) according to the 
manufacturer’s instructions.
Anchorage independent growth assays
Cells were plated at 5000 cells/well in 6-well plates in 
triplicates in soft-agarose. For tet-inducible EGFP-KRAS 
expression, doxycycline (100 ng/ml) was included in both 
the agarose-media mix. Cells were allowed to grow for 
16 days. Colonies were stained with 0.005% crystal violet 
in 5:4:1 methanol: water: acetic acid. Colonies were quan-
tified using the Alpha Innotech Imaging Station Colony 
Counter Software.
Population doubling
Stably transduced SAEC-hTERT-sh_p16, SAEC-GFP-
sh_p16, SAEC-GFP-FF2, and untransduced SAECs were 
seeded in a 6-well plate and continuously passaged in 
log-phase for approximately 90 days. Media was changed 
every other day, and population doubling was meas-
ured every three to four days when confluency reached 
80–90%.
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